LBT Innovations Limited

What LBT Innovations Limited does

LBT Innovations Limited is a publicly listed Australian company (ASX: LBT) that designs and commercializes AI-driven imaging technology for automated analysis of microbiology culture plates. Its core product, the APAS Independence, is an FDA-cleared in-vitro diagnostic instrument that uses computer vision to image, interpret, and report microbial growth on agar culture plates following incubation, replacing the manual reading step that has historically been performed by microbiologists in pharmaceutical and clinical laboratories. The technology was developed by microbiologists specifically for microbiology workflows and is supported by more than 25 peer-reviewed publications validating its clinical performance.

The company operates under the Clever Culture Systems commercial brand and sells a platform-plus-modules product architecture: the core APAS Independence instrument is complemented by Pharma Modules (for pharmaceutical environmental monitoring and quality control) and Clinical Modules (for urine screening, infection control, and antimicrobial susceptibility testing), plus Digital Reporting capabilities. Revenue is generated through capital-equipment sales of the APAS Independence instrument and recurring software/services streams tied to the installed base. The company pursues an enterprise field-sales go-to-market, with global headquarters in Adelaide, Australia, and direct sales and service offices in Irvine, California (USA) and Pfäffikon (Switzerland) to cover the global pharmaceutical and clinical laboratory markets.

Name

LBT Innovations Limited

Legal name

LBT Innovations Limited

Website

https://lbtinnovations.com

Company type

Public

Founded year

2012

Operating status

Operating

Headcount range

11–50 employees

Short description

LBT Innovations Limited (ASX: LBT) designs AI-powered automated microbiology culture plate reading instruments (APAS Independence) for pharmaceutical environmental monitoring and clinical laboratories globally, commercialized under the Clever Culture Systems brand.

Ownership category

akta.pro rank

Product category

Microbiology Lab Instruments

NAICS

Analytical Laboratory Instrument Manufacturing (334516)

SIC

Laboratory Analytical Instruments (3826)

akta.pro primary industry

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)

Keywords

• Automated microbiology imaging
• AI culture plate reading
• In-vitro diagnostic instruments
• Environmental monitoring automation
• Clinical lab AI software

Headquarters

HQ city

Adelaide

HQ country

Australia

HQ region

Oceania

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

1. APAS Independence Instrument Sales: Sale of the APAS Independence in-vitro diagnostic instrument to pharmaceutical and clinical laboratories. The instrument automates culture plate reading for microbiology labs.
2. Software/Subscription Services: Ongoing software updates, maintenance, and support services for the APAS Independence system, likely delivered as recurring revenue.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

LBT Innovations (commercially branded as Clever Culture Systems) designs, manufactures, and sells the APAS Independence, an AI-powered in-vitro diagnostic instrument that automates the imaging, interpretation, and reporting of microbial growth on agar culture plate media for pharmaceutical and clinical laboratories. The flagship instrument is complemented by dedicated Pharma Modules and Clinical Modules that apply the underlying AI platform to environmental monitoring and clinical diagnostics workflows respectively.

Product overview

Clever Culture Systems offers a platform-plus-modules architecture centered on the APAS Independence intelligent automated microbiology culture plate reading system. The core product (APAS Independence) provides automated imaging, analysis, and interpretation of agar culture plates using proprietary AI technology developed by microbiologists. This core platform is complemented by specialized modules: Pharma Modules for pharmaceutical environmental monitoring and quality control applications, and Clinical Modules for urine screening, infection control, and antimicrobial susceptibility testing. Additional features include Digital Reporting for enhanced result traceability. The system serves both pharmaceutical and clinical laboratory markets, functioning as an in-vitro diagnostic instrument for automated culture plate analysis.

Differentiator

Problem solved

Functional benefit

Brands

• APAS Independence: AI-powered intelligent automated microbiology culture plate reading technology that automates imaging, interpretation, and reporting of microbial growth on culture plate media for pharmaceutical and clinical laboratories.

Products and services

• APAS Independence An intelligent automated microbiology culture plate reading instrument that automates the imaging, interpretation, and reporting of microbial growth on agar culture plate media for pharmaceutical and clinical laboratories. It is an FDA-cleared in-vitro diagnostic instrument and the only scientifically proven instrument using artificial intelligence to read environmental monitoring culture plates following incubation.
• Pharma Modules AI-powered application modules tailored for pharmaceutical laboratory workflows, including environmental monitoring plate reading and quality control processes for pharmaceutical production environments. Sold as part of the APAS Independence platform offering.
• Clinical Modules AI-powered application modules tailored for clinical laboratory workflows, including urine screening for urinary tract infection, infection control, and antimicrobial susceptibility testing. Sold as part of the APAS Independence platform offering.

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Scale indicators1 record

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Becton, Dickinson and Company (BD): BD's Kiestra line is a leading automated microbiology specimen processing and incubation system for clinical labs. It is the most direct large-incumbent competitor to APAS Independence, with deep global installed bases and broader lab-automation portfolios.
• bioMérieux: bioMérieux is a global leader in clinical and industrial microbiology diagnostics, offering culture-based identification, AST, and lab automation. It competes across both pharma EM and clinical microbiology where APAS Independence is sold.
• Beckman Coulter (Danaher): Beckman Coulter provides clinical lab automation and diagnostics instrumentation. It is comparable to LBT as a broad lab-instrumentation incumbent with overlapping clinical microbiology customer relationships.
• Roche Diagnostics: Roche is a major clinical diagnostics player with microbiology and lab-automation offerings. Comparable to LBT as a large established vendor to clinical laboratories seeking workflow automation and standardized result reporting.
• Abbott Diagnostics: Abbott provides clinical diagnostics instruments and informatics to hospital and reference labs. It is comparable to LBT as an incumbent diagnostic platform vendor with overlapping clinical lab customer base and broader portfolio.

Direct peers

• Copan Diagnostics: Copan's WASPLab and WASP systems automate specimen processing and culture plate imaging for clinical microbiology labs. Like LBT, Copan targets culture-plate workflow automation and is a direct competitor in clinical lab AI plate reading.

Emerging players

• Accelerate Diagnostics: Accelerate Diagnostics offers rapid identification and antimicrobial susceptibility testing in clinical microbiology. Comparable to LBT as an emerging clinical-microbiology automation vendor, though it targets rapid molecular workflows rather than culture-plate AI.
• T2 Biosystems: T2 Biosystems develops rapid molecular diagnostics for sepsis and other bloodstream infections. It is comparable to LBT as a smaller clinical-microbiology technology vendor competing for microbiology lab automation budgets.
• Selux Diagnostics: Selux Diagnostics is developing rapid AST systems for clinical microbiology labs. It overlaps with LBT's clinical microbiology customer base as a competing emerging automation and AST platform vendor.

Others

• Hamilton Company: Hamilton produces laboratory automation robots and workstations used in clinical and pharmaceutical labs. Comparable to LBT as an enabling lab-automation vendor that addresses similar workflow bottlenecks in pharma and clinical laboratories.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

• YouTubeyoutube.com/channel/UCOqOo6xq888wimACrBdMwmw
• LinkedInlinkedin.com/company/13467610
• Xx.com/LBTInnovations

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries1 record

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LBT Innovations Limited